首页 › 胶质母细胞瘤 › 阿拉巴马州 › Birmingham
Birmingham AL 胶质母细胞瘤临床试验
9项针对 胶质母细胞瘤的研究正在 Birmingham及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
招募中2/3 期
- University of Alabama at Birmingham, Birmingham
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
招募中2 期
- University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
招募中1/2 期
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
招募中1 期
- University of Alabama at Birmingham Cancer Center, Birmingham
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- University of Alabama, Birmingham
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
招募中2 期
- University of Alabama at Birmingham Cancer Center, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
招募中
- University of Alabama at Birmingham, Birmingham
Study of Pembrolizumab and M032 (NSC 733972)
招募中1/2 期
- University of Alabama at Birmingham, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Birmingham
其他城市的 胶质母细胞瘤试验
- New York City, NY30 项研究
- Boston, MA28 项研究
- Houston, TX26 项研究
- Los Angeles, CA24 项研究
- Durham, NC20 项研究
- San Francisco, CA17 项研究
- Chicago, IL15 项研究
- Washington, DC15 项研究
- Columbus, OH14 项研究
- Miami, FL14 项研究
- Rochester, MN13 项研究
- Jacksonville, FL13 项研究
Birmingham的其他研究
- 癌症（所有类型）31 项研究
- 乳腺癌24 项研究
- 卵巢癌23 项研究
- 肥胖症23 项研究
- 非小细胞肺癌22 项研究
- 急性髓系白血病21 项研究
- 多发性骨髓瘤18 项研究
- 慢性阻塞性肺病17 项研究
- 心血管疾病17 项研究
- 2型糖尿病16 项研究
- 子宫内膜癌16 项研究
- 超重16 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。